Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 9/20 | 0.40 |
| ▸ | QPCT | Q16769 | 7/20 | 0.40 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099427 | 0.83 | MEN1 (0.38) | PDE4BPDE4DGSK3BALDH1A1HPGD | |
| SCHEMBL6100637 | 0.73 | HTR6 (0.54) | — | |
| SCHEMBL6347654 | 0.72 | GSK3B (0.41) | GSK3BQPCTKDM4EALDH1A1HPGD | |
| SCHEMBL9732323 | 0.72 | BCHE (0.55) | PDE4BPDE4DALDH1A1 | |
| SCHEMBL6098592 | 0.71 | PPARD (0.48) | ALDH1A1 | |
| SCHEMBL6097457 | 0.70 | HTR6 (0.45) | — | |
| SCHEMBL6100606 | 0.69 | PPARD (0.46) | — | |
| SCHEMBL5879148 | 0.69 | KDR (0.57) | PDE4BKDM4EALDH1A1RAB9AHSD17B10 | |
| SCHEMBL6099511 | 0.68 | MAOB (0.41) | PRKD1TDP1GSK3BQPCTRAB9A | |
| SCHEMBL6799799 | 0.68 | PPARG (0.41) | RAB9ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | PDE4B 2551/4885PDE4D 3211/4885PRKD1 835/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | PDE4B 2586/4885PDE4D 3323/4885PRKD1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.